Psychedelics like psilocybin, MDMA, and ketamine are emerging as promising therapeutic tools for mental health issues. Here's ...

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

'Functional unblinding was a major barrier to the approval of psychedelics as medicines to treat the patients who need them most,' said Dr. Andrew Chadeayne, CaaMTech CEO. 'I'm incredibly proud that ...

Atai Life Sciences N.V. ( (ATAI) ) has released its Q3 earnings. Here is a breakdown of the information Atai Life Sciences N.V. presented to ...

Top-line data for its phase 2b trial studying GH001 is expected either in the fourth quarter of 2024 or the first quarter of ...

MONTPELIER, Vt. (WCAX) - A new report shows Vermont may not move forward -- yet -- on psychedelic therapy.

New framework introduces comprehensive guidelines for assessing side effects in psychedelic-assisted therapies, aiming to ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Completed dosing of 115 participants in a bioavailability and bioequivalence (BA/BE) clinical trial in Australia for IHL-42X, an investigational treatment for obstructive sleep apnea in July 2024.

Recent research indicates that psychedelics can be effective in treating conditions such as depression, post-traumatic stress ...

Over the course of a lifetime, as many as seven in 10 adults in the United States will directly experience or witness harrowing events. These include gun violence, car accidents, and other personal ...